Image by Vektor Kunst from Pixabay
The FDA on Thursday revised its guidance on postmarket adverse event reporting for medical products and dietary supplements during a pandemic to apply the guidance to the ongoing coronavirus disease (Covid-19) pandemic.
The guidance, which applies to drugs, biologics, medical devices, combination products and supplements, details how FDA intends to prioritize adverse event reporting requirements during a pandemic.
Click here to read full article https://endpts.com/fda-revamps-adverse-event-reporting-guidance-for-covid-19/
